Top Markets
#1 Islamic Coin Islamic Coin +155.97%
#2 Siren Siren +37.56%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.25%
#4 Verus Coin Verus Coin +22.40%
#5 Cysic Cysic +19.84%
#6 Arowana Arowana +19.40%
#7 OpenEden OpenEden +17.23%
#8 Perle Perle +14.78%
#9 Ocean Protocol Ocean Protocol +13.13%
#10 RedStone RedStone +12.61%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
PCL, Inc. PCL, Inc.

PCL, Inc.

241820
Rank in Stocks #31791
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic... PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
Share Price
$0.21291741
Last synced: 2025-04-18
Market Cap
$12.07M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
KR
Trade PCL, Inc. (241820)

Category

Healthcare
Revenue for PCL, Inc. (241820)
Revenue in Sep 2025 TTM: $3.55M
According to PCL, Inc. latest financial reports the company's current revenue (TTM) is $3.55M. In 2023 the company made a revenue of $6.51M a decrease compared to the revenue in the year 2022 that was $29.49M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PCL, Inc. from 2015 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $3.55M 318.67%
2024 $847.63K -86.98%
2023 $6.51M -77.92%
2022 $29.49M -24.02%
2021 $38.82M -21.50%
2020 $49.45M 159,346.74%
2019 $31.01K -73.14%
2018 $115.44K -75.69%
2017 $474.92K -2.74%
2016 $488.29K 136.13%
2015 $206.79K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 $46.59B 1,312,601.74%
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 $25.84B 727,951.41%
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 $35.48B 999,790.71%
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 $21.00B 591,538.63%
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 $6.51B 183,407.73%
US